AngioDynamics (NASDAQ:ANGO) Updates FY 2022 Earnings Guidance

AngioDynamics (NASDAQ:ANGO) updated its FY 2022 earnings guidance on Thursday morning. The company provided earnings per share guidance of $0.000-$0.050 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.010. The company issued revenue guidance of $310 million-$315 million, compared to the consensus revenue estimate of $307.82 million.

Shares of NASDAQ ANGO opened at $25.93 on Thursday. The stock has a 50 day moving average price of $26.71 and a 200 day moving average price of $25.56. AngioDynamics has a 52 week low of $10.17 and a 52 week high of $30.25. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.60 and a current ratio of 2.45. The stock has a market capitalization of $1.00 billion, a PE ratio of -31.62 and a beta of 0.83.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings results on Thursday, September 30th. The medical instruments supplier reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.03. AngioDynamics had a positive return on equity of 0.41% and a negative net margin of 10.84%. The firm had revenue of $77.00 million during the quarter, compared to analysts’ expectations of $71.31 million. During the same period in the prior year, the firm posted $0.02 earnings per share. The business’s quarterly revenue was up 9.7% compared to the same quarter last year. As a group, research analysts forecast that AngioDynamics will post 0.01 EPS for the current year.

Several research firms have issued reports on ANGO. Oppenheimer began coverage on AngioDynamics in a research note on Friday, August 20th. They issued a market perform rating on the stock. Raymond James raised their price objective on AngioDynamics from $27.00 to $32.00 and gave the stock a strong-buy rating in a research note on Friday, July 9th. Canaccord Genuity raised their price objective on AngioDynamics from $24.00 to $28.00 and gave the stock a hold rating in a research note on Wednesday, July 14th. Finally, TheStreet upgraded AngioDynamics from a d+ rating to a c rating in a research note on Tuesday, July 13th. Three research analysts have rated the stock with a hold rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, AngioDynamics has a consensus rating of Buy and a consensus price target of $27.33.

In other AngioDynamics news, SVP Chad Thomas Campbell sold 10,748 shares of the firm’s stock in a transaction on Tuesday, October 5th. The stock was sold at an average price of $27.15, for a total value of $291,808.20. The sale was disclosed in a filing with the SEC, which is available at this link. Company insiders own 3.80% of the company’s stock.

An institutional investor recently raised its position in AngioDynamics stock. Morgan Stanley lifted its position in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 88.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 289,456 shares of the medical instruments supplier’s stock after acquiring an additional 135,460 shares during the quarter. Morgan Stanley owned approximately 0.75% of AngioDynamics worth $7,853,000 at the end of the most recent reporting period. Institutional investors own 96.45% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical device company, which engages in the development, manufacture, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. It offers ablation systems, fluid management systems, vascular access, angiographic, drainage. thrombolytic, and venous products.

Featured Story: What are the advantages to having securities held in street name?

Earnings History and Estimates for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.